Author/Authors :
Jafari, Leila Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Hajifathali, Abbas Hematopoietic Stem Cell Research Center - Shahid Beheshti University of Medical Sciences,Tehran, Iran , Mohammadi, Mohammad Hossein Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ghaedi, Hamid Department of Medical Genetics - Faculty of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Allahbakhshian Farsiani, Mehdi Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Amiri, Vahid Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Hosseini, Maryam Sadat Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Roshandel, Elham Hematopoietic Stem Cell Research Center - Shahid Beheshti University of Medical Sciences,Tehran, Iran , Gharehbaghian, Ahmad Department of Hematology and Blood Banking - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Background: Acute graft versus host disease (aGVHD) is a common complication following allogeneic hematopoietic stem cell
transplantation (AHSCT) caused by cellular andinflammatory factors, including those arising from monocytes and dendritic cells as
integral parts of theimmunesystem. Long non-coding RNAs (lncRNA) have recently emerged as potential regulators of theimmune responses and it is supported that their dysregulation can develop various immune disorders. As an intergenic lncRNA, the lnc DC was shown to regulate the human monocytes differentiation and antigen presenting cells (APCs) activation during immune responses. It is also shown that lnc-DC knockdown reduces T-cell activation and cytokine release.
Objectives: The aim of this study was to assess whether the lnc-DC plays a role in patients with aGVHD by measuring its expression levels compared to non-aGVHD patients on specific time intervals following transplantation.
Methods: Participants included 38 patients who underwent primary allogeneic bone marrow transplantation. Peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient from the blood samples collected at days 0, 7, 14, 28, and final day of transplantation. The qRT-PCR was used to quantify the lnc-DC levels.
Results: Findings revealed a significant increase in the lnc-DC levels on day 28 and the final day after transplantation in patients
with aGVHD compared to non-GVHD patients (CI = 95%, P < 0.03 on day 28 and P < 0.01 on the final day). Furthermore, the receiver operating characteristic (ROC) curve analysis showed an acceptable total area under the curve for the lnc-DC gene expression data, suggesting a fair diagnostic value for lnc-DC.
Conclusions: Taken together, data of the present study supported a strong correlation between lncRNA-DC expression and aGVHD occurrence. As a result, lnc-DC may be considered as a new molecular marker for the aGVHD prognosis.
